Fig. 1.

Fig. 1. Shikonin attenuated palmitic acid (PA)-induced muscle atrophy in C2C12 myotubes. (A) Immunofluorescence staining for myosin heavy chain (MHC) 24 h after treatment. Scale bars represent 100 μm. (B) Quantification represents the diameter of myotube. (C) RT-qPCR analysis of the mRNA levels of MAFbx and Murf1 in shikonin-treated C2C12 myotubes. (D) Immunoblotting for MHC-T, MHC-I, MHC-IIa, MHC-IIb, and β-actin of shikonin-treated C2C12 myotubes. All quantifications were performed in three independent experiments (n = 3). Error bars represent the standard deviation (SD). *p < 0.05, **p < 0.01 and ***p < 0.001 versus control (CON; PA treatment). Statistically significant differences were determined using one-way ANOVA followed by Tuckey’s post-hoc test.

© J. Microbiol. Biotechnol.